Accendra Health vs Henry Schein
Henry Schein reported revenue of $13.2 billion in fiscal 2025, 4.8 times Accendra Health's $2.8 billion in fiscal 2025. Accendra Health's revenue grew 3.1% in its latest year, and Henry Schein's grew 4.0%. Accendra Health had an operating margin of 1.0%, against 5.0% at Henry Schein. Free cash flow was −$293 million at Accendra Health and $573 million at Henry Schein. Their fiscal years end in different months (December 31 and December 27), so the periods don't line up exactly.
Side by side
| Accendra Health | Henry Schein | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 27, 2025 |
| Revenue | $2.8B | $13.2B |
| Revenue growth | 3.1% | 4.0% |
| Revenue growth a year, last 5 years | −20.1% | 5.4% |
| Gross margin | 46.7% | 31.1% |
| Operating margin | 1.0% | 5.0% |
| Net margin | −39.9% | 3.0% |
| Free cash flow | −$293M | $573M |
| Free cash flow margin | −10.6% | 4.3% |
| Return on capital | 1.2% | 7.5% |
| Net debt to EBITDA | 7.3x | 3.1x |
| Dividends and buybacks | $10M | $850M |
| Change in diluted share count | 0.2% | −4.7% |
| Last close | $0.09 | $84.80 |
| P/E at the last close | — | 23.2× |
| Insider trades, last 12 months | sold $4,046 | bought $691,900, sold $8.6 million |
| Piotroski F-score | 2 of 9 | 6 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Accendra HealthHenry Schein
Operating margin
Percent of revenue
Accendra HealthHenry Schein
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Accendra HealthHenry Schein
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Accendra Health and Henry Schein pages.